Robert Driscoll
Stock Analyst at Wedbush
(1.85)
# 3,206
Out of 4,959 analysts
147
Total ratings
29.41%
Success rate
-7.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Neutral | $19 → $4 | $5.67 | -29.45% | 6 | Jul 22, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $15.06 | +79.28% | 1 | Jul 14, 2025 | |
| KURA Kura Oncology | Reiterates: Outperform | $36 | $7.65 | +370.59% | 10 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.99 | +101.01% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.32 | +354.55% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $37.01 | +81.03% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.82 | +252.70% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.32 | +63.93% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $7.20 | +344.44% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $25.12 | +107.01% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $11.71 | +139.11% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.92 | +447.95% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $10.53 | +184.90% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $9.79 | +420.94% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.73 | +587.66% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $8.19 | +339.56% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.65 | +568.69% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.56 | +133.81% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.90 | +88.41% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $24.30 | +204.53% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.02 | +164.90% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.46 | +379.45% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.12 | +277.36% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.59 | +11.42% | 4 | May 19, 2020 |
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $4
Current: $5.67
Upside: -29.45%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $15.06
Upside: +79.28%
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $7.65
Upside: +370.59%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.99
Upside: +101.01%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.32
Upside: +354.55%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $37.01
Upside: +81.03%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.82
Upside: +252.70%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.32
Upside: +63.93%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $7.20
Upside: +344.44%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $25.12
Upside: +107.01%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $11.71
Upside: +139.11%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.92
Upside: +447.95%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $10.53
Upside: +184.90%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $9.79
Upside: +420.94%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.73
Upside: +587.66%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $8.19
Upside: +339.56%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.65
Upside: +568.69%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.56
Upside: +133.81%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $6.90
Upside: +88.41%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $24.30
Upside: +204.53%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.02
Upside: +164.90%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.46
Upside: +379.45%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.12
Upside: +277.36%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.59
Upside: +11.42%